PositiveID Corporation Publishes Its Featured Presentation From Biodetection Technologies 2013 Conference


Chief Technology Advisor Dr. Kimothy Smith's presentation available on PositiveID's website

DELRAY BEACH, Fla., June 18, 2013 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today published to its website a presentation given by Chief Technology Advisor Dr. Kimothy Smith at the 21st International Conference for Biodetection Technologies 2013 in Alexandria, VA. The presentation, which can be viewed at http://www.positiveidcorp.com/investors_events.html, focuses on the Company's technological advances in the detection and identification of biological threats, specifically, its patented M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) and Firefly Dx detection system ("Firefly").

PositiveID's M-BAND system, developed under contract with the U.S. Department of Homeland Security Science & Technology directorate, is a bio-aerosol monitor with fully integrated systems for sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins. Results are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments.

The goal of Firefly is to take the Company's patented molecular diagnostic technology underlying M-BAND, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents. Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed. Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. The Company believes the target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including, without limitation, the likelihood that results from M-BAND are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments; the likelihood that the goal of Firefly is to take the Company's patented molecular diagnostic technology underlying M-BAND, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents; the likelihood that Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed; the likelihood that Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application; the likelihood that target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the biological detection and diagnostic sectors; the Company's ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 16, 2013 under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.



            

Coordonnées